405279-59-6Relevant articles and documents
Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012
Melancon, Bruce J.,Lamers, Alexander P.,Bridges, Thomas M.,Sulikowski, Gary A.,Utley, Thomas J.,Sheffler, Douglas J.,Noetzel, Meredith J.,Morrison, Ryan D.,Scott Daniels,Niswender, Colleen M.,Jones, Carrie K.,Jeffrey Conn,Lindsley, Craig W.,Wood, Michael R.
, p. 1044 - 1048 (2012/03/11)
This Letter describes the continued optimization of an MLPCN probe molecule (ML012) through an iterative parallel synthesis approach. After exploring extensive modifications throughout the parent structure, we arrived at a more highly M1-selective antagonist, compound 13l (VU0415248). Muscarinic subtype selectivity across all five human and rat receptors for 13l, along with rat selectivity for the lead compound (ML012), is presented.